FDA plans to begin a pilot in 2022 on unannounced foreign inspections of foreign drug facilities, in response to concerns that facilities in China and India are able to fix problems before announced inspections to evade FDA enforcement, according to a GAO report released Feb. 7. Likewise, the agency also will soon run a pilot on use of independent translators for inspections in China and Hong Kong, rather than relying on translators provided by the inspected facility.
On Feb. 4, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Feb. 3, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA has issued its Enforcement Report for Feb. 2, listing the status of recalls and field corrections for food, cosmetics, tobacco products, drugs, biologics and devices. The report covers both domestic and foreign firms.
On Feb. 2, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Feb. 1, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Jan. 31, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Jan. 27, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Jan. 26, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA has issued its Enforcement Report for Jan. 26, listing the status of recalls and field corrections for food, cosmetics, tobacco products, drugs, biologics and devices. The report covers both domestic and foreign firms.